ExpiresOctober 3, 2020
Format TypeJournal-based CME
This JAMA Insights article explains cell-free circulating tumor DNA and its utility in noninvasive cancer detection and characterization, prediction of treatment response, monitoring of disease relapse, and identification of mechanisms of resistance to targeted therapies.
1. This activity is accredited by the American Medical Association.
2. This activity is free to AMA members.
ABMS Member Board Approvals by Type
ABMS MOC Part II CME Activity
Allergy and Immunology
Colon and Rectal Surgery
Medical Genetics and Genomics
Physical Medicine and Rehabilitation
Psychiatry and Neurology
NOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.
To understand technology used for establishing diagnoses based on analysis of circulating DNA.
Cancer Biomarkers, Oncology, Surgical Oncology, Pathology and Laboratory Medicine, Targeted and Immune Cancer Therapy
CME Credit Type
AMA PRA Category 1 Credit